News
MultiKano is the first automatic cell type annotation method tailored to single-cell multi-omics data. MultiKano introduces a novel data augmentation strategy based on paired scRNA-seq and scATAC ...
Researchers at VCU Massey Comprehensive Cancer Center have developed a new computational tool called Vesalius, which could ...
6don MSN
Human hippocampal neurogenesis shows unique gene expression patterns compared to other mammals
While the process via which different types of neurons are produced, also known as neurogenesis, has been the focus of ...
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy ...
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of ...
Data were derived from Rickels MR, et al. Improvement in glycemic control and elimination of exogenous insulin use in patients with type 1 diabetes infused with fully differentiated islet cells ...
Sana Biotechnology will present clinical data on UP421, a hypoimmune islet cell therapy for type 1 diabetes, at an upcoming symposium.
11don MSN
Molecular characterization of a rare type of lung cancer may point the way to a treatment target
Large cell neuroendocrine carcinoma (LCNEC), a rare and aggressive type of lung cancer, has a high chance of metastasis, no standard treatment and a poor survival rate. A study published in Nature ...
A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...
An off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results, according to a new study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results